Short answer
AVANOS MEDICAL, INC. (AVNS) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $178M (up 4.3% year over year) with net income of −$1M.
Q3 2025 key financials · XBRL
- Revenue
- $178M
- +4.3% YoY · +1.6% QoQ
- Net income
- −$1M
- −132.6% YoY · +98.2% QoQ
- Operating margin
- 0.1%
- Gross margin
- 48.4%
- EPS (diluted)
- −$0.03
- −133.3% YoY · +98.2% QoQ
Source: XBRL data from the AVANOS MEDICAL, INC. (AVNS) Q3 2025 10-Q on SEC EDGAR. USD.
AVANOS MEDICAL, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue and YoY change not provided in supplied MD&A excerpt
- Goodwill impairment $77.0M for PM&R reporting unit
- Q3 restructuring costs $10.3M vs $2.3M YoY
- Nexus acquisition for $27.0M cash, plus up to $20.0M contingent consideration
- Expanded restructuring plan: up to $10.0M incremental costs and $15.0M–$20.0M annualized savings through 2026
Risk Factors
- New tariff risk triggered by U.S. tariffs imposed since February 2025 and potential retaliatory measures
- Supply-chain exposure from manufacturing concentrated in Mexico and foreign sourcing including China
- Medicare coverage risk from proposed MAC policies questioning peripheral nerve RFA reimbursement, with determination expected early 2026
- Revenue risk from reduced foreign demand if retaliatory tariffs increase product costs in Europe, Asia, and Latin America
- Reimbursement pressure from payor discounts, price reductions, and coverage limitations affecting customer purchasing decisions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AVANOS MEDICAL, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.